UNSPSC 51202408: Eculizumab

This classification denotes an immunomodulator, an immunosuppressant, and monoclonal antibody, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier A3ULP0F556. Most nations, for tariff and trade purposes, schedule Eculizumab under HS 30021091 and SITC 54163. SMILES:. As of Q4 2014, ECULIZUMAB remains US FDA's Preferred Term for this commodity.. Eculizumab bears US NLM identifiers UMLS ID C1541483 and NCI Concept Code C48386.

UNSPSC 51202408 Eculizumab is a Commodity code tracking a single pharmaceutical product, but the recent state and local opportunities posted under it do not align with procurement of this specific biologic drug. Instead, the code shows activity spanning a broader range of pharmaceutical and medical supply acquisitions: naloxone and drug deactivation systems for community health support, generic multi-source pharmaceuticals and over-the-counter products through cooperative purchasing, direct-to-manufacturer prescription programs, and medical and first aid supplies for emergency response. The issuing bodies include health departments, fire departments, cooperative purchasing alliances, and state health and human services commissions, suggesting that the code may be misfiled or used as a catch-all for pharmaceutical and medical commodity procurement more broadly.

Activity appears across Florida, Minnesota, Texas, and Oregon, with the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) administering a significant RFP for generic pharmaceuticals and OTC products due March 26, 2026. The City of Tampa issued an IFB for medical and first aid supplies (Solicitation 26P00145) with a response deadline of March 13, 2026 and an estimated contract value of $700,000.00, designated as a sheltered market for certified Small Local Business Enterprises with a 5 percent bid discount. Seminole County, Florida solicited naloxone and drug deactivation systems through an IFB (IFB60459723LAS) with a response deadline of July 26, 2023. The Texas Health and Human Services Commission issued a Request for Information (RFI HHS0017013) on March 27, 2026 to explore direct-to-manufacturer prescription programs. Given the mismatch between the code's nominal scope and the actual solicitations, firms pursuing this code should verify that individual opportunities align with their product or service lines before investing in pursuit strategy.